Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$70.13 ▲ +0.74
(+1.07%)
MKT CAP: $16.93B • VOL: 5.59M
52W L $36 52W H $72
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$59
MEDIAN
$79
MEAN
$80
HIGH
$95
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE EXEL TAPE
EXEL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $84.86 | $80.65 | 2025-02-14 | $63.82 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $88.36 | $82.75 | 2025-02-06 | $65.92 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $79.95 | $77.14 | 2025-01-29 | $67.32 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $71.53 | — | 2025-01-17 | $68.73 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $61.71 | $66.62 | 2025-01-09 | $62.42 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $83.45 | $72.94 | 2024-12-18 | $61.01 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $68.03 | $70.83 | 2024-12-04 | $65.22 | -4.3% | 48% | C |